NEW YORK, NY–(Marketwired – Sep 11, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration’s (FDA) Fast Track program. Late last week Celgene announced that the FDA has approved its supplemental new drug application for ABRAXANE® when
Read more →SILVER SPRING, MD–(Marketwired – Sep 10, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Fisher BioServices, Inc. for the long-term storage of cells that will be required for its future Phase 3 and other cancer
Read more →PharmaCyte Biotech Launches New Corporate Website SILVER SPRING, MD–(Marketwired – Aug 23, 2013) – PharmaCyte Biotech, Inc. (OTCQB:NVLX) (Company), an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, announced today that the Company has restructured corporate operations in an effort to
Read more →